Testosterone Prescribing Rules by State for TRT Clinics

Testosterone is a Schedule III controlled substance under federal law, which means a prescription can be refilled no more than five times and no later than six months after it was issued. That federal floor is the same in every state. Everything a TRT clinic actually trips over sits in the state layer: who may prescribe under a protocol or agreement, whether the state prescription drug monitoring program (PDMP) must be checked first, and whether a state adds its own steroid rules.

We checked the primary sources for 13 states (Texas, Florida, California, New York, Georgia, Ohio, North Carolina, Arizona, Colorado, Washington, New Jersey, Pennsylvania, and Michigan). The biggest surprise is New York, which schedules testosterone as Schedule II under state law: no refills, a 30-day supply cap, and a PMP check before every prescription. On PDMPs, a check is mandatory before a testosterone prescription up front in 5 of the 13 states (Florida, California, New York, Michigan, and Pennsylvania), and in Ohio once treatment passes 90 days. In the other seven, the mandate covers opioids, benzodiazepines, or a short list that does not include testosterone.

Federal telemedicine flexibilities for controlled substances end after December 31, 2026 unless DEA finalizes a replacement; our DEA telemedicine post covers that clock. This guide is for practices (physician, NP, and PA) and not for patients. Current as of October 2026.

What federal law requires for every testosterone prescription

Testosterone is listed as an anabolic steroid in 21 CFR 1308.13(f), which includes “testosterone (17β-hydroxyandrost-4-en-3-one)” and its salts, esters, and ethers (drug code 4000). The statutory definition in 21 U.S.C. 802(41)(A) reaches “any drug or hormonal substance, chemically and pharmacologically related to testosterone” other than estrogens, progestins, corticosteroids, and DHEA. DEA’s controlled substance list places testosterone in Schedule III. Because the schedule attaches to the substance, compounded testosterone is Schedule III too.

Refills. 21 CFR 1306.22(a) says no Schedule III or IV prescription “shall be filled or refilled more than six months after the date on which such prescription was issued,” and one authorized for refills “may not be refilled more than five times.” A 30-day prescription with five refills therefore runs exactly six months. A 10-week prescription with five refills would run 60 weeks on paper but expires at six months. The prescriber decides how many refills to authorize; after six months a new prescription is required.

Prescription content. 21 CFR 1306.05(a) requires every controlled substance prescription to be dated and signed on the day issued and to carry the patient’s full name and address, drug name, strength, dosage form, quantity, directions for use, and the practitioner’s name, address, and registration number. Under 1306.05(e), an electronic prescription must be created and signed “using an application that meets the requirements of part 1311.”

DEA registration follows the location. 21 CFR 1301.12(a) requires “a separate registration” for each principal place of business or professional practice at one general physical location. Under 1301.12(b)(3), a practitioner’s office is exempt from a separate registration only when it is in the same state as the practitioner’s registered location, controlled substances are prescribed but not administered or dispensed there, and no supplies are kept. Prescribing to patients in another state falls outside that exemption, which is why multi-state prescribers hold a registration tied to a location in each state. It is also why DEA’s proposed special registration would add a state telemedicine registration for each state (see the DEA post).

One in-person evaluation. An Internet prescription of a controlled substance is valid only if the practitioner “has conducted at least 1 in-person medical evaluation of the patient” under 21 U.S.C. 829(e)(2)(A)(i). Under 21 CFR 1307.41, the telemedicine flexibility covers the period “May 12, 2023, through December 31, 2026” and “expires at the end of December 31, 2026.” We do not restate the special registration proposal here; the DEA post has it.

Can a nurse practitioner or physician assistant prescribe testosterone?

Yes for NPs in every one of the 13 states we checked, and for PAs in the six states where we verified PA rules (Texas, Florida, California, Ohio, Pennsylvania, and Michigan), but the terms differ. Whether a state is full, reduced, or restricted practice for NPs changes the agreement you need, not the schedule of the drug. For the 50-state practice authority and ownership table, see NP weight loss clinic ownership by state. We do not repeat it. The Schedule III specifics:

Most other limits in these states cap Schedule II only (for example, Florida’s 7-day Schedule II supply and Ohio’s 72-hour terminal-condition rule for Schedule II). Texas and Pennsylvania are the two where a supply cap reaches Schedule III. For the full startup picture, see the NP clinic startup checklist.

Testosterone prescribing rules by state

The table covers the four things a clinic asks first. “No state rule found” means we did not find one in the sources we checked, not that none exists. PA authority is shown only where we verified it (see the note after the table).

State NP and PA authority; supply limits reaching Schedule III Mandatory PDMP check reaches testosterone? In-person or telehealth rule for controlled substances Steroid-specific rule
Texas Delegated under a prescriptive authority agreement; 90-day limit including refills, then physician consultation (Occ. Code 157.0511) No. Mandate covers “opioids, benzodiazepines, barbiturates, or carisoprodol”; other drugs permissive (H&S 481.0764) Telemedicine prescribing requires a physician-patient relationship and compliance with chapters 481 and 483, effective January 9, 2025 (22 TAC 175.3); no state in-person rule for Schedule III found Anabolic steroid in Schedule III only “for a valid medical purpose”; bodybuilding by a healthy person is not one (H&S 481.071)
Florida APRN under an on-site protocol; PA by delegation, with 3 of 10 CME hours on controlled substance prescribing (464.012; 458.347); no Schedule III limit found Yes, before any controlled substance for a patient age 16 or older; if not consulted, document why and limit to a 3-day supply (893.055(8)) Telehealth bars Schedule II only (with exceptions), so Schedule III is not barred (456.47(2)(c)); e-prescribing required for practitioners who maintain an EHR (456.42(3)) Testosterone and esters listed in state Schedule III (893.03); no separate steroid-purpose rule found
California NP by standardized procedure with a patient-specific protocol for Schedule III; PA by practice agreement or patient-specific order (2836.1; 3502.1); no Schedule III supply limit found Yes (CURES): before the first Schedule II, III, or IV prescription and at least every six months on renewal (H&S 11165.4) A prior examination “can be achieved through the use of telehealth”; federal in-person rule still applies (B&P 2242); e-prescribing required (B&P 688) No steroid-specific rule found
New York NP under a written practice agreement (3,600-hour exemption) (Educ. Law 6902); state Schedule II rules apply; PA not verified Yes: every Schedule II, III, or IV prescription (PHL 3343-a) “No controlled substance shall be prescribed prior to an in-person medical evaluation,” with a telehealth exception tied to DEA rules (10 NYCRR 80.63); e-prescribing required (PHL 281) Testosterone is state Schedule II (PHL 3306); no refills, 30-day cap (10 NYCRR 80.67)
Georgia Nurse protocol agreement; no Schedule I or II; quarterly physician review of controlled substance records (Rule 360-32-.02); PA not verified No. Required for benzodiazepines and Schedule II opiates; every 90 days thereafter (Georgia DPH) Prescribing “based solely on a consultation via electronic means” is unprofessional conduct unless within a valid relationship, on-call coverage, or an emergency, amended effective August 27, 2024 (Rule 360-3-.02; see also 360-3-.07) No steroid-specific rule found
Ohio CNP under a standard care arrangement; Schedule II limited to a 72-hour terminal-condition dose, no Schedule III limit in the statute (ORC 4723.481); PA by delegation, DEA-registered (ORC 4730.41) Yes, after 90 days of treatment, then at least annually (OAC 4731-11-11) Boards may require an initial in-person visit for Schedule II only, effective April 9, 2025 (ORC 4743.09) Physician may not use testosterone or HCG “for the purpose of enhancing athletic ability” (OAC 4731-11-03)
North Carolina Schedules II to V as set in the collaborative practice agreement, NP DEA number on each prescription (21 NCAC 36.0809); PA not verified No. Covers “targeted controlled substances” (Schedule II and Schedule III opioids) (90-113.74C; 90-87) No controlled-substance telehealth statute found No steroid-specific rule found
Arizona RNP authorized by the Board after pharmacology education; no Schedule II opioid dispensing; no Schedule III limit found (R4-19-511); PA not verified No. Covers opioid analgesics and benzodiazepines (A.R.S. 36-2606(E)) Out-of-state telehealth providers must register with the PDMP before prescribing a controlled substance to an Arizona patient (A.R.S. 36-3606) Unprofessional conduct to prescribe anabolic-androgenic steroids “for other than therapeutic purposes” (A.R.S. 32-1401(27)(ii))
Colorado APRN prescriptive authority after a 750-hour mentorship (C.R.S. 12-255-112); PA not verified; no Schedule III limit found No. Covers opioids and benzodiazepines (C.R.S. 12-280-404) No controlled-substance telehealth statute found No steroid-specific rule found
Washington ARNP may prescribe Schedules II through IV within board-defined scope (RCW 18.79.250; 18.79.240); PA not verified No. Mandate tied to opioid prescribing and listed medications; no query mandate for non-opioid Schedule III (WAC 246-919-985) No controlled-substance telehealth statute found No prescribing “to increase muscle mass, strength, or weight, or to enhance athletic ability” without medical necessity; gross misdemeanor (RCW 69.41.320; 69.41.300)
New Jersey APN under joint written protocols with a collaborating physician; CDS on a separate NJ prescription blank (N.J.A.C. 13:37-7.9); PA not verified Only with a reasonable belief of misuse, abuse, or diversion for a non-opioid, non-benzodiazepine Schedule III drug (13:45A-35.9) Initial in-person exam and in-person visits every three months, Schedule II only (13:35-6B.6) No steroid-specific rule found
Pennsylvania CRNP: Schedule III or IV up to 90 days (21.284); PA: agreement must list categories not permitted (18.158) Yes: first controlled prescription for each patient, which a first testosterone prescription triggers (PA Dept. of Health) No controlled-substance telehealth rule found No steroid-specific rule found
Michigan APRN and PA may prescribe schedules 2 to 5 as delegated; both DEA numbers recorded (MCL 333.17211a; 333.17076); no Schedule III limit found Yes, for any controlled substance quantity above a 3-day supply (MCL 333.7303a(4)) Requires a bona fide prescriber-patient relationship, which allows the medical evaluation “in person or through telehealth” (MCL 333.7104) No steroid-specific rule found

Not verified. We omitted Illinois and Tennessee because we could not confirm them from a primary source. The Illinois legislature’s site failed our link check and no primary copy of the PMP statute (720 ILCS 570/314.5) was retrievable; the collaborative agreement rule at 68 Ill. Adm. Code 1300.465 (Schedule II 30-day supply) is cited in our NP post, but the PDMP rule could not be confirmed. For Tennessee, the state site served a bot page for the controlled substance monitoring database report and FAQ, and the APRN controlled substance rule text was not retrievable. PA prescribing authority in New York, Georgia, North Carolina, Arizona, Colorado, Washington, and New Jersey was not researched for this guide, so the PA details above are filled in only for Texas, Florida, California, Ohio, Pennsylvania, and Michigan.

Which states require a PDMP check before prescribing testosterone?

A mandatory check reaches testosterone in six of the 13 states, on different triggers.

State When the check is required for testosterone
Florida Before prescribing any controlled substance (patient age 16 or older); exceptions include nonopioid Schedule V and hospice
California Before the first Schedule II, III, or IV prescription, then at least once every six months if renewed; report obtained no earlier than 24 hours or the previous business day before prescribing
New York Before every Schedule II, III, or IV prescription
Michigan Before prescribing a controlled substance in a quantity above a 3-day supply
Pennsylvania The first time a patient is prescribed any controlled substance by the prescriber, and when the prescriber has reason to believe the patient may be abusing or diverting drugs
Ohio Once treatment lasts more than 90 days, then at least annually

Sources are in the state table above (Florida 893.055, California 11165.4, New York 3343-a, Michigan 7303a, Pennsylvania, Ohio 4731-11-11). Ohio’s rule has exceptions for hospice, inpatient, treatment of 7 days or less, cancer, and surgical acute pain.

In Texas, Georgia, North Carolina, Arizona, Colorado, Washington, and New Jersey, the mandate is limited to opioids, benzodiazepines, or a short list of drugs, so testosterone is outside it. Texas makes a check before other controlled substances permissive. New Jersey requires one for a non-opioid, non-benzodiazepine Schedule III drug only when there is a reasonable belief of misuse, abuse, or diversion.

Why does New York treat testosterone as Schedule II?

New York’s Public Health Law lists “Anabolic steroids” under Schedule II(h), including “Testosterone (17{beta}-hydroxyandrost-4-en-3-one),” while chorionic gonadotropin (hCG) is Schedule III(g) (PHL 3306). That makes hCG a separate controlled substance in New York. The consequences come from 10 NYCRR 80.67:

A multi-state practice cannot copy its Schedule III workflow into New York. A 30-day prescription with five refills is valid under the federal rule and invalid in New York.

Does a TRT patient need an in-person exam?

Federally, one. 21 U.S.C. 829(e) requires at least one in-person medical evaluation, defined as one “conducted with the patient in the physical presence of the practitioner, without regard to whether portions of the evaluation are conducted by other health professionals.” DEA’s flexibility under 21 CFR 1307.41 lets practitioners prescribe controlled substances by telemedicine without that visit through December 31, 2026. The DEA post covers what replaces it.

States layer their own rules on top:

For state telehealth standard-of-care rules that apply to any prescription, see GLP-1 telehealth prescribing rules by state.

Which states have anabolic-steroid-specific laws?

Four of the 13 states define what is not a valid medical purpose for anabolic steroids:

In the other nine states we found no steroid-specific rule. The general standard of care and the diagnosis requirements below still apply.

What does the chart have to show for TRT?

Three written sources describe the same documentation, and a regulator’s order shows the cost of skipping it.

FDA label. The testosterone cypionate injection label (updated October 22, 2026) gives the indication as replacement therapy in males with conditions associated with deficiency or absence of endogenous testosterone: primary hypogonadism and hypogonadotropic hypogonadism. It states that safety and efficacy in men with “age-related hypogonadism” have not been established. Before starting, the prescriber should “confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range.”

FDA class-wide labeling, February 28, 2025. FDA required a new warning about increased blood pressure, and recommended adding the TRAVERSE trial results (no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism), “removing language from the Boxed Warning related to an increased risk of adverse cardiovascular outcomes,” and “retaining ‘Limitation of Use’ language for age-related hypogonadism” (FDA).

Endocrine Society guideline. The 2018 guideline (Bhasin et al., J Clin Endocrinol Metab 2018;103(5):1715-1744) says to diagnose hypogonadism only in men with symptoms and signs and “unequivocally and consistently low serum T concentrations,” using fasting morning total testosterone with an accurate and reliable assay, confirmed by repeating the measurement. In the full text (the PubMed record carries the abstract), the lower limit of normal is harmonized to 264 ng/dL for CDC-certified assays. It advises against starting therapy in men with breast or prostate cancer, a palpable prostate nodule, PSA above 4 ng/mL, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, thrombophilia, or near-term fertility plans.

The guideline’s monitoring schedule (Table 9 of the full text):

What to monitor Interval
Clinical evaluation 3 to 12 months after starting, then annually
Hematocrit Baseline, 3 to 6 months after starting, then annually; if above 54%, stop until it falls to a safe level, then restart at a reduced dose and evaluate for hypoxia and sleep apnea
PSA and digital prostate exam Baseline and at 3 to 12 months; a confirmed PSA rise above 1.4 ng/mL over baseline in the first 12 months triggers urological consultation; after one year, follow standard screening guidelines

Medicare contractor expectations. A cash-pay clinic is not bound by a Medicare local coverage determination, but Noridian LCD L36538 (revision effective October 16, 2025) is the clearest written statement of what a reviewer expects to see. It calls for “at least 2 separate serum testosterone levels taken on two different days in the morning” plus a single LH or FSH, symptoms documented in the chart, and states that “Low serum testosterone alone does not constitute a diagnosis of androgen deficiency or clinical hypogonadism.” It also says “Ongoing monitoring of hormone levels and side effects are necessary.”

What missing documentation costs. The Washington Medical Commission’s legal actions list for November 1, 2023 through January 31, 2024 records an Agreed Order dated November 16, 2023 against a physician assistant for “Failure to meet standard of care in prescribing testosterone for male hypogonadism.” The sanctions included a restriction from prescribing testosterone without oversight and approval of a supervising physician who is a board-certified endocrinologist, urologist, or equivalent, a clinical competency assessment, CME on prescribing testosterone, treating hypogonadism, informed consent, and record keeping, compliance audits, and a fine. We did not find a Texas Medical Board or Florida Board of Medicine order specific to TRT from a government source, and we make no claim about either.

Consent and records. Washington’s order names informed consent as a required CME topic, RCW 69.41.320(2) requires records of the diagnosis and purpose, and Michigan’s MCL 333.7104 requires records “in accordance with medically accepted standards.” For telehealth encounters, identity and location capture are covered in the DEA post and the GLP-1 telehealth post.

Can a clinic use compounded testosterone or pellets?

Compounded testosterone is a 503A product. The exemption applies if it is compounded for an identified individual patient based on a valid prescription order, by a licensed pharmacist or physician, and the compounder does not compound regularly or in inordinate amounts drug products that are “essentially copies of a commercially available drug product.” FDA’s position is that “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug” (FDA compounding Q&A, current as of September 16, 2025). The essentially-a-copy mechanics are in our compounded GLP-1 post, and the same logic applies to a compounded testosterone cream or injectable at strengths close to an approved product.

On hormone compounding generally, FDA asked the National Academies in September 2018 to study compounded bioidentical hormone therapy, including testosterone. NASEM delivered its analysis on July 1, 2020 and determined “there was a lack of rigorous evidence of safety and effectiveness from well-designed or properly controlled clinical studies” (FDA).

Pellets follow the same rule: compounded pellets are 503A products that need a patient-specific prescription. For the branded pellet, Noridian’s contractor medical directors state that use should be rare since the “accepted method of medical practice” is to administer testosterone transdermally, while allowing that there may be reasons requiring the implanted form (Noridian billing article A55056, revision effective November 6, 2025). On billing, the insertion is a separate minor procedure from the pellets themselves, and that is as far as this guide goes.

Checklist before you prescribe testosterone in a new state

This guide summarizes statutes, rules, and agency pages as we found them in October 2026. It is not legal advice, rules and board positions change, and a state we checked is not a state we verified for your specific license type or practice model. Confirm current text with the state board and your counsel before you rely on it.


Your clinic’s chart has to hold the labs, the consent, the monitoring plan, and the prescription, all in one place. PrismEHR includes eRx with DEA-compliant EPCS, telehealth, secure messaging, medication history and interaction checking, documentation templates, and a patient portal. See how it fits wellness, longevity, and weight loss practices. Related reading: compounded GLP-1 prescribing rules.